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Abstract
Background: Interest in assessing the value of health-care services in Germany has considerably
increased since the foundation of the Institut für Qualität und Wirtschaftlichkeit im
Gesundheitswesen, IQWiG (Institute for Quality and Efficiency in Health Care). The practical
application of value assessment illustrates how problematic the process can be. In all decisions
made for the provision of health care, data concerning the measurable dimensions (quantity and
quality of efficacy and effectiveness, validity of the results and costs) flow into a complex and not
yet standardized decision-making process concerning public financing. Some of these decisions are
based on data of uncertain validity, unknown reproducibility and unclear appropriateness.
Discussion: In this paper we describe the theoretical aspects of value from psychological and
economic viewpoints and discuss national and international approaches. Methodic details and
difficulties in assessing the value of health-care services are analysed. A definition of the intangible
value of health-care services will be proposed which contains only three factors: the absolute risk
reduction (usually a measure of efficacy), the validity of the scientific papers examined and the type
of the expected effectiveness (prevention of death and disability, restitution of well-being). The
intangible value describes the additional benefit when comparing two possible actions, like
treatment or observation only.
Conclusion: The description of intangible value from the viewpoint of different stakeholders is a
useful measure for subsequent steps (not discussed here) – the evaluation of costs and of patient
benefit. A standardised, transparent, fair and democratic evaluation is essential for the definition of
a basic benefit package.
Background
The foundation of the Institut für Qualität und Wirt-
schaftlichkeit im Gesundheitswesen, IQWiG (Institute for
Quality and Efficiency in Health Care) exemplified the
need for a scientific and independent evaluation of
health-care services in Germany. Since a basic benefit
package should be publicly financed, the assessment of its
value cannot rely merely on supply and demand. The
problem arises due to the different points of view con-
cerning what is adequate, appropriate and economic. The
definition of this range of services is a political decision
which should be supported to the greatest possible extent
by scientific data.
For this purpose, institutions have been established in dif-
ferent European states and in Australia and Canada to
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carry out a scientific evaluation of the available data
[assessment] and then to perform a political interpreta-
tion and make decisions [appraisal]. In most countries,
these two steps – assessment and appraisal – are per-
formed by separate and independent institutions. The
pioneering function of Anglo-Saxon countries is plausible
because the necessity of making transparent decisions in
their health-care systems, which are financed by the
national treasury, is considerably greater than in systems
which are based on private and social insurance systems.
In most industrialized countries, health care is one of the
most important market segments and, therefore, has con-
siderable importance for the overall economy. Appropri-
ate growth of this market and a high potential for
innovation can be considered positive indicators for the
welfare of a nation. The market and its innovations can
hardly be controlled by uniform viewpoints if the value of
its products cannot be measured. Without knowing the
values of a culture, the appropriateness of prices can
hardly be judged. Our considerations on this subject have
been summarized in two books, 'Klinische Ökonomik'
(Clinical Economics) [1] and 'Optimizing Health –
Improving the Value of Healthcare Delivery' [2].
The aim of this paper is to propose and discuss procedures
to assess the value of publicly-financed health-care serv-
ices. The procedures must be reliable and valid and
should be applicable in all health-care systems. To achieve
the defined goal, theoretical aspects of value are discussed
from economic and psychological points of view, and the
problem of the general measurability of value is
addressed.
Discussion
Concepts of value
As various disciplines investigate different aspects of value
assessment, a short theoretical excursion may be helpful
in the discussion of a new concept.
Economic value
The classics of economic theory apply an objective, cardi-
nal term for value which is oriented to the recognized
value of a commodity for the satisfaction of specific needs,
like the caloric value of coal or the highest permitted
speed of a car. The neoclassical theory of value, in con-
trast, proceeds from an ordinal, subjective concept of
value in which an absolute measurability of value is
rejected in favour of individual hierarchies of preference
[3].
Psychological value
In the field of psychology, value is defined as subjective
well-being and divided into different dimensions. Pleas-
ant emotions, unpleasant emotions and cognitive life sat-
isfaction are differentiated [4].
Operationalisation
Definition of value
In economic theory, value is understood as the measure-
ment of the ability of a good or an object to satisfy the
needs of an economic stakeholder (like a consumer).
Need is defined as the attempt to relieve discomfort
through a certain action. This concept is also applied in
the classic definition of quality in DIN ISO 9000:2000.
Types of value
The households of microeconomic consumption theory
are maximisers of value in their consumption demands.
They measure the quality of consumed goods as the
degree of received value.
The contributions of the school of marginal costs (the
value of an additional unit of a good) and the introduc-
tion of the term 'subjective utility' as an individual assess-
ment of a good as an exchange or utilitarian object by the
evaluator led to the identity of utilitarian or exchange
value.
Households, as well as users of health-care services,
behave rationally in that the overall value of the con-
sumed goods is as high as possible under the budgetary
limitations of the available income. In public health-care
systems, the users of health-care services also behave
rationally in that the overall value of the consumed goods
is as high as possible, but not – and this makes the differ-
ence – limited by their own income. The users try to get
"unlimited health care". As a consequence, not the users
of health-care services, but others, have to make the deci-
sions about the allocation of health-care resources. These
proxy decisions are rather difficult to make due to the dif-
ficulty of measuring the value of health care.
Measurability of value
The usual techniques applied by economists [5-8], like
standard gamble and time trade off, are excellent for the-
oretical considerations, but cannot be applied to daily
clinical practice. Ten minutes of the doctor's full attention
and the perception of empathy are much more valuable to
patients than twenty business minutes of the doctor's time
budget. In other words, a formal expression of the value
of health care may be plausible for policy considerations
of health-care managers, but not for individual patients
who have a serious problem.
The standardized assessment of quality of life or of well-
being is obviously problematic because each individual
does not measure his/her received value on these scales,
but in other terms. This has recently been shown inBMC Health Services Research 2007, 7:1 http://www.biomedcentral.com/1472-6963/7/1
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patients with different types of cancer. These patients
exhibit different individual preferences for health-related
quality of life [9]. Breast-cancer patients under treatment
wish to avoid nausea/vomiting, pain and a decrease in
emotional and role functioning. Patients with colorectal
cancer listed nausea/vomiting and diarrhoea before pain
and role functioning, and for patients with lung cancer, it
was more important to avoid dyspnea than other symp-
toms.
International assessment of health-care services
A synopsis of the procedures used in different countries
carried out for the Deutsches Institut für Medizinische
Dokumentation und Information, DIMDI (German Insti-
tute for Medical Documentation and Information) pro-
vides a comprehensive description of the complexity of
decision-making processes, the institutions involved and
the methods used to make these decisions [10]. Without
going into the details of the analysis, it becomes clear that
the complex process of evaluation must eventually lead to
a one-dimensional decision – whether a health-care serv-
ice is to be fully, partly or not publicly financed. Even this
carefully performed analysis cannot represent the applied
procedures with sufficient clarity to make them compre-
hensible.
Far more problematic than measurement is the assess-
ment of these results. It is not described anywhere in the
included value assessments which criteria of value, like
ameliorating chronic complaints in degenerative diseases,
are compared with the value of a therapy which could pre-
vent the late results of a disease if compliance is high.
How scientific papers describing important clinical effects
(like prevented deaths) not supported by valid data are
evaluated remains unclear.
American authors [11] requested 225 leading internists to
estimate the importance to patients of 30 medical inter-
ventions. The experiment took the inevitable subjective
viewpoints of the assessors into consideration. Although
different aspects of this procedure are open to criticism,
the procedure appears to indicate how a consensus on
useful results can be reached.
Unfortunately, similar uncertainties observed in effects
are also reflected in costs. The critical evaluation of 89
cost-utility ratios from 40 oncology studies demonstrates
that the validity of many of these examinations are ques-
tionable when carefully analysed [12].
National assessment of health-care services
It is probably no coincidence that the term 'value' is often
addressed, but not explicitly stated anywhere in the Ger-
man Drug Law. This law defines pharmaceutical drugs as
substances or preparations from substances with which
physical or mental suffering can be cured, lessened, pre-
vented or recognized. A generally accepted definition of
the value of health services would also prove helpful here.
The legal foundation for the assessment of the value of a
drug can be found in the Sozialgesetzbuch [Code of Social
Law]. Paragraph 1 (V, §35b) states that the Institute for
Quality and Efficiency in Health Care determines uniform
methods to establish the evaluation of value and publi-
cises them in the internet. Paragraph 2 describes the test-
ing and, if necessary, alteration of these methods.
A rational examination of scientific criteria can only be
carried out on the basis of a scientific discussion. There-
fore, scientific suggestions stemming from different
national institutions for assessing the value of health-care
services will be summarised in the appendix.
Both psychology and economics offer several theoretical
approaches to define the value of health care, but health-
care professionals are not satisfied with either of them,
and it seems they are not applicable. Economics reduces
the economic stakeholder, in simple terms, to a purely
economic being who is driven solely by self-interest and
behaves purely according to rational criteria. One of the
core assumptions is the principle of marginal costs and
marginal benefit. This concept does not add value if the
choice is only being alive or dead. Another problem
emerges when life-threatening situations are implicitly
considered in discussions about the value of health-care
services, neglecting the large variety of services ranging
from rescue to cosmetic interventions.
The "homo economicus" desires to equalise the marginal
value of his/her various consumer possibilities and,
thereby, to maximize his/her overall value. The desire for
value among all members of society creates a demand for
goods, which determines the supply structure via the mar-
ket-price mechanism. The market-price mechanism itself
depends on limitations, such as scarcity of goods and the
available budget. As there is no real limitation on many
"goods" (except rationing) in the health-care market as
long as the public pays for them, an essential control
mechanism is lacking in publicly-financed health care.
The laws of economics will be more effective in a pri-
vately-financed health-care sector. The critical solution
needed for all health-care systems is the assessment of
value in the public sector.
The meaning of value in psychology, with its goals of hap-
piness and well-being, more closely resembles the opin-
ion of sick persons than the economic concept. The
meaning of death for terrorists is completely different
from that of chronically-ill persons. In medicine, the con-
cept of benefit or value is not standardised, which can beBMC Health Services Research 2007, 7:1 http://www.biomedcentral.com/1472-6963/7/1
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explained by the lack of a theory of medicine [13].
Because medicine is an empirical science without a theo-
retical basis (bio-molecular foundations cannot replace a
theory of medicine), uniform definitions of health, sick-
ness and the value of health services are lacking. This lack
of a fundamental theory explains the reluctance of physi-
cians to discuss theoretical aspects of medicine.
Many physicians also feel uncomfortable with the
methodic requirements of clinical epidemiology unless
psychological aspects of daily medical practice are consid-
ered. Clinical science is impossible without stringent epi-
demiologic methods.
• Almost all of the data used in cost-benefit analyses
derive from clinical studies, which assessed the efficacy,
but not effectiveness (effects under everyday conditions)
of treatment. This problem refers to the interface of clini-
cal epidemiology and economics.
• The methods used in economic analyses (like "time
trade-off" – how many years of life would you be willing
to forfeit if you could exchange your present health condi-
tion for optimal health) do not, in contrast to the opin-
ions of some economists, have anything to do with
clinical reality in our culture. Most patients value life and
struggle for each day they can remain alive. This is a prob-
lem at the interface of psychology and economics.
• The last statement is supported by data which demon-
strate that patients generally place a high value on life,
regardless of its quality [14,15]. In quality-of-life research
the phenomenon of "response shifts" is known. Self-
assessed quality of life describes the relationship between
the individual's expectations and observations. Most
patients report the same quality of life even during pro-
gression of their disease associated with an increase in
problems and impairments. The most likely explanation
for this observation is the adaptation of the patient's
expectations to reality. Lowered expectations correspond
with the observed situation, resulting in a stable quality of
life.
• The generic instruments for quality-of-life assessments
preferred by economists (comparing outcomes in differ-
ent diseases) are too insensitive to detect small, but signif-
icant, treatment effects. Therefore, psychologists develop
highly specific questionnaires to detect aspects that are
important to patients. Physicians who are socialised in a
bio-molecular world disregard the "soft" research con-
ducted by psychologists and prefer to base their decisions
on "hard facts", such as laboratory results and imaging
methods, that are often irrelevant to patients and of
unknown prognostic significance.
It may seem strange that most of the studies and presenta-
tions cited in the appendix of the national assessment of
health-care services were directly or indirectly initiated by
the pharmaceutical industry. One reason is that the proof
of effectiveness of drugs is one of the business founda-
tions of the pharmaceutical industry and that experience
with such instruments and methodic expertise are availa-
ble there. Unfortunately, the purchasers of health-care
services are often unfamiliar with the theories behind
their decisions. Values from the viewpoint of different
stakeholders are usually not taken into consideration.
To bridge this gap we introduce the term "intangible
value" of health-care services. This concept combines
aspects of clinical epidemiology and psychology to form a
basis for necessary economic assessments. Value is consid-
ered as an additional benefit obtained by possible alterna-
tive actions. Even if there appears to be only one possible
mode of action or therapy, there are always the two possi-
bilities of either applying the existing option or not. Rea-
sons for not applying it could be undesired side effects,
like high monetary costs or impairment of quality of life.
To reach a consensus on the definition of the value of
health-care services, we assume that the value relevant for
making a decision coincides with the subjectively per-
ceived value. The actually achieved value influences the
perceived value, but is not relevant for making a decision.
Most decisions reached in the health-care system cannot
be explained by considering only the actually confirmed
value. If 1000 women undergo mammography within a
time interval of 10 years, death as a result of breast cancer
can be prevented in one woman. About 970 of these 1000
women receive the anticipated information following the
examination that no adverse finding could be detected.
One can now pose the question whether this examina-
tion, which is important to many women, is largely
demanded due to the perceived or the actually guaranteed
safety [16].
The term 'intangible value' in analogy to the term 'intan-
gible costs' is used to illustrate that the concept of subjec-
tively perceived value used here is considered
independent of monetary costs. The intangible value of a
health-care service coincides with the added value which
is perceived to be provided by the new service in compar-
ison to already existing services. This intangible value is
defined by three dimensions:
• the effects expressed as absolute risk reduction (ARR),
• the validity (V) of epidemiologic and of economic data
andBMC Health Services Research 2007, 7:1 http://www.biomedcentral.com/1472-6963/7/1
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• the type of expected effectiveness (TEE) (saved life or
alleviated complaints under day-to-day conditions).
The parameters measured as endpoints of clinical studies,
like prolongation of survival, improvement in quality of
life, lowering of high blood pressure, changes that can be
identified in imaging procedures, undesired side effects of
drugs, and increased compliance, are considered "effects".
Effects are expressed as absolute risk reduction (ARR).
This describes the number of patients that have to be
treated to observe a specific problem (e.g., death, recur-
rence of malignant disease, or headache) in the experi-
mental-treatment group in one case less than in the
control group.
The collection and description of the data (assessment) in
these three categories, ARR, V and TEE, require specialist
knowledge. Experts are superior to laypersons in the
assessment. Specialists, however, are less adept in the
interpretation (appraisal) of the measured data because
the interpretation is made according to subjective (!) cri-
teria.
Absolute risk reduction (ARR)
Evidence-based medicine groups in Hamilton, Ontario
(Canada) and Oxford (England) were very effective in dis-
seminating the rules of clinical epidemiology and other
helpful principles for medical decision making. Therefore,
it can be anticipated that medical students are familiar
with the concepts of risk reduction.
Validity (V)
To avoid subjective, arbitrary evaluations, we propose let-
ting all groups which participate in the value assessment
evaluate the validity. This requires that all members of
these groups have a basic knowledge of epidemiology,
which can be attained quickly [17,18] and with an accept-
able amount of effort. Aside from the studies and meta-
analyses cited above, which support the view that the role
of randomisation is overestimated, the apparently
unproblematic differentiation between randomised and
non-randomised studies could contribute to the overesti-
mation of this criterion of validity. A further criterion of
validity, blinding/masking, can be just as important as
randomisation. Preventing unmasking, which is as impor-
tant as masking, is considerably more difficult to maintain
and to identify in a published study than the difference
between a randomised and a non-randomised study. This
example shows that the validity of scientific statements
can only be confirmed by paying attention to details.
Even in qualitatively well performed meta-analyses of
treatment studies the validity is not formally taken into
consideration when calculating the effect. In other words,
studies with low validity – if they are not excluded by the
authors of meta-analyses due to considerable deficiencies
– influence the result of a meta-analysis to the same
degree as valid studies. In nearly all evaluations, it is, how-
ever, the importance relegated to the published data is
decisive in the decision-making process. Studies in which
very big effects are described contain a priori a higher
validity risk than studies in which small effects are
described.
Type of expected effectiveness (TEE)
An unsolved problem is how realistically the results of
controlled studies which have been conducted under
ideal conditions (e.g. a randomised controlled trial) can
actually be applied to everyday conditions. It is almost
impossible to maintain the inclusion and exclusion crite-
ria and other conditions prevailing in a controlled study
under everyday conditions. Maintenance of these condi-
tions in a controlled study is, however, essential to be able
to confirm the described effects with scientifically recog-
nized methods. It is also hardly possible to realistically
demonstrate "minor" improvements in the quality of care
with the traditional methods of clinical studies. By minor
improvements we mean, for example, modifications
which improve compliance. It is easy to imagine that an
improvement in patient compliance is unimportant in a
clinical study because close controls take care of the prob-
lem of compliance. Under everyday conditions, however,
improved compliance can exert a considerable influence
on outputs and outcomes. Therefore, the classification as
a "minor" advantage may simply be wrong.
Evaluations, for example, of an improvement in hearing,
childlessness, false teeth, or innovative therapies for incur-
able diseases are problematic and are made primarily by
decision makers. The perceived suffering is correlated with
the recognised value of the therapeutic measure. The
greater the suffering, the higher the value attributed to the
appropriate treatment. Non-affected (healthy) laypersons
are probably not inferior to experts in making these deci-
sions because experts cannot avoid their specialty biases
[19,20].
In summary, the data of the three measurable dimensions
(effect expressed as ARR, validity, and type of expected
effectiveness) are subject to complex and hitherto incom-
prehensible processes which result in a decision concern-
ing public financing. The rules for these decisions have to
be defined to guarantee consistency and reproducibility.
To our understanding, the term "intangible value"
includes multidimensionality (i.e., several product char-
acteristics are taken into consideration, like therapeutic
and non-therapeutic, objective and subjective criteria,
desired and undesired effects), complexity (i.e., evaluated
from different perspectives, like patient [intended or
unwanted effects], physician [effectiveness], healthBMC Health Services Research 2007, 7:1 http://www.biomedcentral.com/1472-6963/7/1
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insurer [efficiency], transparency (i.e. differentiation
between objective assessment and subjective interpreta-
tion) and time dependency (i.e., the expected effect can be
delayed and is temporally limited).
Finally we propose an emerging model for assessment of
the "intangible value" to be applied by decision makers
representing the important stakeholders in a health-care
system, e.g., 37.5% recipients of health-care services
(insured individuals), 37.5% providers of health-care
services, (i.e., 25.0% specialist societies and 12.5% indus-
try), 15.0% public payers of health-care services (insur-
ances), and 10.0% independent experts (scientists).
These members may be appointed for a limited period
(like 4 years) and replaced every half year. The procedure
for choosing members within the individual groups
should reflect the actual spectrum of the insured individ-
uals, service providers, and payers of health-care services.
After short training in epidemiologic foundations of the
evaluation of scientific data, this panel will present the
health services which are to be evaluated. The panel mem-
bers are able to understand scientific data on effect, effec-
tiveness and validity of data and are aware of the
limitations of objective evaluation. The data for the effects
and validity will be presented to the panel members by
"independen" scientists (as far as they can be independ-
ent, e.g. from NICE in the UK or IQWiG in Germany).
Based on this presentation the panel members interpret
three dimensions of the presented data – the absolute risk
reduction (ARR), the validity (V), and the type of expected
effectiveness (TEE) – by using a score point system (Table
1) which is subject to validation.
There will not be much variation in the interpretation of
the efficacy, which is usually expressed as absolute risk
reduction (ARR) [21,22]. A maximum of ten points can be
reached for ARR > 40%. The range of 9.9 – 9.0 points is
proposed for ARR = 39%–25%; 8.9 – 8.0 for ARR = 24 –
15%; 7.9 – 7.0 points for ARR = 14 – 10%; 6.9 – 6.0 points
for ARR = 9 – 5% and 5 points for ARR < 5%.
In contrast, the interpretation of the validity of scientific
reports varies considerably. It has recently been shown
that application of the criteria of the CONSORT statement
improves the reporting of clinical trials [23,24]. Unfortu-
nately, these recommendations [25-28] are not always
accepted [29]. A more general problem is the inclusion of
clinical trials in systematic reviews. Although there are rec-
ommendations for the inclusion or exclusion of trials [30]
in systematic reviews, the impact of trials included in a
systematic review is generally independent of its validity.
We consider this to be a serious problem, as the chance to
produce the expected results in experimental studies
increases with decreasing validity of the studies. There-
fore, we propose incorporating the validity (V) of the ana-
lysed studies in our model. This is achieved by
multiplication by a simple validity factor which is 1.0 if
the validity of a study is not impaired at all. This factor
may be as low as 0.1 in studies with seriously impaired
validity. Further details are shown in Table 2.
The third variable which has to be included in the score of
intangible value is the type of expected effectiveness
(TEE), which actually inccorporates two aspects. First, it
differentiates between treatments that are life-saving (TEE
= 10.0) or just avoid disturbances in well-being (TEE = 3.9
to 1.0). A more detailed proposal for assessments is
Table 1: Calculation of the "intangible value"
Dimensions influencing the "intangible value" Comparison between effects of two treatment 
options
Results based on scientific result or consensus
Absolute Risk Reduction [ARR] ARR>40%:10 pts;
39-25%: 9.9-9.0 pts;
24-15%: 8.9-8.0 pts,
14-10%: 7.9-7.0 pts;
9-5%: 6.9-6.0 pts;
ARR<5%: 5 pts
Absolute risk reduction (ARR) = 14% 7.6 
points
Validity [V] Validity (multiplier for not impaired validity = 
1.00, for seriously impaired validity = 0.10)
Subjectively determined validity factor: 0.90
Type of expected effectiveness [TEE] Type of expected effectiveness (TEE) (multiplier 
for prevention of: death = 10.0; life-threatening 
event = 9.9-9.0; considerable disability = 8.9-7.0; 
dis-ability = 6.9-4.0; disturbance in well-being = 
3.9-1.0
Subjectively determined type of exp. 
effectiveness (TEE) = 9.2
Intangible value (product of ARR score) × (validity 
factor) × (TEE)
Intangible value = 7.6 points × 0.90 × 9.2 = 62.9 
points
The difference in effects (absolute risk reduction) is expressed in score points. These points are multiplied by a validity factor and factor describing 
the type of expected effectiveness. The given example assumes an ARR = 14%, high validity (0.90) und important type of expected effectiveness 
(9.2). The calculated intangible value is 62.9 points.BMC Health Services Research 2007, 7:1 http://www.biomedcentral.com/1472-6963/7/1
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shown in Table 2. The second aspect which is included in
the TEE value is the difference between efficacy (assess-
ment under ideal conditions) and effectiveness (assess-
ment under everyday conditions). Data that describe the
relationship between efficacy and effectiveness are lack-
ing. As treatment effects are usually assessed under ideal
conditions, i.e. the efficacy, but not the effectiveness, is
assessed, we can describe their expected (type of expected
effectiveness), but not their real effectiveness. The TEE
value therefore includes the estimated difference between
efficacy and effectiveness.
The panel should only evaluate health services for which
a discussion of public financing by authorized institutions
is expected. A two-step procedure can be performed to
attain the expected added value of these health services.
First step: The attainable scientific data on which the com-
parative evaluation of at least two procedures is based
(database) are elucidated. A date for the presentation of
the question and the preliminary data is set with the
panel. The database is made available to the members of
the panel. Scientists present the essential data which
describe the efficacy or effectiveness of the examined serv-
ice, as well as the validity of the studies examined. The
panel should have sufficient time to comprehend the pre-
sented results based on the available documents and to
formulate complementary questions.
Second step: Within three weeks a second step is initiated.
At this time the members of the panel ascertain in a writ-
ten procedure (the voting person is not identified, but the
group to which s/he belongs is) the intangible value as
described above.
Even this simplified evaluation can be based on very com-
plex considerations. In 2001 the WHO presented the
"International Classification of Functioning, Disability
and Health (ICF), which is analogous to the International
Classification of Diseases (ICD). This classification does
not offer a quantitative evaluation because this would be
subject to considerable variation due to the subjective
points of view. The ICF lists all aspects which should be
considered in the complex evaluation of the performance
category.
The resulting intangible value has to undergo a validation
process. The proposed model which takes the intangible
value into consideration might be a first step towards a
synthesis of aspired goals defined by health-care practi-
tioners and methods contributed by economists.
Summary
The ongoing discussion in Germany about the value of
health care and its public financing triggered this sum-
mary of existing models for assessment of the value of
health care. We address some limitations of these models
and propose a method that is based on three variables: the
efficacy of the service, the validity of the scientific reports
and the type of expected effectiveness. The last variable
includes two estimates – the value of alleviation of a
symptom or the prevention of death and the probability
that the effect which was measured under the ideal condi-
tions of a controlled clinical trial will also occur under
everyday conditions. The (not yet validated) product of
these three variables provides a figure that can be used for
comparisons and may be useful for the definition of a
basic benefit package.
Abbreviations
ARR Absolute risk reduction
BAH Bundesverband der Arzneimittelhersteller (Federal
Association of Drug Manufacturers)
Table 2: Suggested factors (range 1.0 – 0.1) for evaluation of the validity [V] of scientific papers and the assessment of type of expected 
effectiveness [TEE] (range 10.0 – 1.0).
Factor Validity Type of expected effectiveness (TEE) × 10 (prevention of ...)
1.00 Not impaired Death
0.99 – 0.90 Almost not impaired with few deficiencies life-threatening event
0.89 – 0.80 considerable impairment
0.79 – 0.70 impaired with deficiencies
0.69 – 0.60
0.59 – 0.50 clearly impaired with obvious deficiencies
0.49 – 0.40 Impairment
0.39 – 0.30 rather impaired with considerable deficiencies
0.29 – 0.20
0.19 – 0.10 seriously impaired disturbed well-being
TEE describes the importance of a health-care service preventing either death, disability, or disturbance in well-being under day-to-day conditions. 
The International Classification of Functioning, Disability and Health (ICF) describes the foundations of this evaluation.BMC Health Services Research 2007, 7:1 http://www.biomedcentral.com/1472-6963/7/1
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BKK Betriebskrankenkassen (Company-affiliated social
health insurances)
BPI Bundesverband der Pharmazeutischen Industrie (Ger-
man Pharmaceutical Industry Association)
DIMDI Deutsches Institut für Medizinische Dokumenta-
tion und Information (German Institute for Medical Doc-
umentation and Information)
DPhG Deutsche Pharmazeutische Gesellschaft (German
Pharmaceutical Association)
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(German Association of Research-Based Pharmaceutical
Companies)
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Appendix
Scientific suggestions for assessment of the value of
health-care services
A position report of the Betriebskrankenkassen, BKK
(Company-affiliated social health insurances) [31] estab-
lished that the effectiveness according to the Arzneimit-
telgesetz (German Drug Law) corresponds with the socio-
legal term "expediency", i.e., with the therapeutic value of
a drug. The service obligation is to be decided based on
cost-benefit considerations. The criteria for the list of rec-
ommended drugs states that the therapeutic value can be
measured by the extent to which the desired therapeutic
effect is attained. This observation is important from a sci-
entific point of view, but the application of different eval-
uation criteria for chemically defined and other drugs
(e.g., from the fields of phytotherapy, homeopathy,
anthroposophy) is problematic. According to this defini-
tion, the therapeutic value of chemically-defined drugs
must be investigated according to evidence-based criteria
while "other" drugs only have to comply with internal
evaluation systems founded on scientific theory.
A position paper [32] of the Verband der Forschenden
Arzneimittelhersteller, VFA (German Association of
Research-Based Pharmaceutical Companies) presented a
detailed suggestion for different criteria which should be
observed in the assessment of the value of drugs. It stated
that the assessment of value should exceed the boundaries
of individual sectors, i.e., should include the prevention
or reduction of hospitalisations, early retirement, nursing
care or visits to physicians. An appropriate point in time
should be chosen for the assessment of value, i.e., the
indication and other circumstances determine how great
the time interval between registration and possible evalu-
ation of value should be because statements concerning
the value of a new therapy immediately following its reg-
istration are, by definition, not possible. Registration usu-
ally results from proof of efficacy, rarely of effectiveness,
and almost never of value. The value of a drug or a health-
care service certainly cannot be sufficiently described by
its efficacy or effectiveness. Therefore, we point out the
necessity of a scientific differentiation between efficacy,
effectiveness and value.
It is also correct that the methodic approach to assessing
value should not be too narrow. The use of only ran-
domised studies – as suggested by German authorities – to
describe the value can hardly be justified scientifically
because these studies have both advantages and disadvan-
tages, just like any other scientific method. Since the
appropriate definition of evaluation criteria represents
one of the greatest problems in assessing value, one must
pay particular attention to maintaining scientific criteria.
Arbitrary rules including minimum times or minimum
dimensions cannot be upheld from a scientific stand-
point. Most complex decisions require a structured dia-
logue, which we confirm to be an essential part of value
assessment.
In its final report on short-acting insulin analogues, the
Institute for Quality and Efficiency in Health Care
demands observation of long-term effects to evaluate ben-
efit and harm [33]. This requirement makes sense if it can
be fulfilled under the prevailing conditions [34]. Since the
required data have not yet been collected and cannot be
handed in within a short time, other ways to assess value
must be discussed.
The report also mentions additional benefit relevant to
the patients [33], but provides no indication of what is
meant by the term additional benefit and with which data
this should be proven. Thus, the statements made by the
Institute for Quality and Efficiency in Health Care do not
make the anticipated contribution to the evaluation of
health-care services.
This impression has been confirmed in a critical statement
[35] concerning the commission and the activities of the
Institute. It has also been accused of a lack of independ-BMC Health Services Research 2007, 7:1 http://www.biomedcentral.com/1472-6963/7/1
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ence and unscientific arguments. This reproach is not
unjustified, since the practicability of generally accepted
assessment rules has been questioned without mention-
ing the available literature on the term value.
The Deutsche Pharmazeutische Gesellschaft, DPhG (Ger-
man Pharmaceutical Association) contributes to the defi-
nition and differentiation of different forms of innovation
in its position paper [35]. When referring to innovation,
"(additional) value" is pointed out along with the "(real)
innovativeness", whereby the former usually can only be
evaluated some time after an innovation has been intro-
duced. In this case, it would be reasonable to name the cri-
teria and the expected time for the confirmation of value
as soon as an innovation is recognised as such.
A comprehensive description of value assessment contain-
ing a summary of the discussed aspects was established by
the Bundesverband der Arzneimittelhersteller BAH e.V.
(Federal Association of Drug Manufacturers) [37]. Therein
from an economic viewpoint value is understood as an
abstract measurement for the satisfaction of needs which
a consumer can get from consuming a good. Value is
equated with health-related quality of life and is, there-
fore, subjective and related to time and place.
This concept is, however, problematic in practical applica-
tion because:
• value must be measurable (objective, interpersonally
comparable and it should be possible to aggregate it as
social benefits),
• value must reflect different perspectives and
• the conflict between individual and social value has to
be solved.
It is shown that socio-legal aspects (expediency, efficiency,
not surpassing the required limits) are necessary, but not
sufficient, criteria for value assessment. Criteria of welfare
economics and regulatory policies can hardly be applied
for value assessment because the physician's decisions
have to be tailored to the individual patient. Even if it
hardly seems possible to take these three aspects into con-
sideration in a common strategy for value assessment, an
approximate solution which is supported by a sufficiently
large majority remains a worthwhile goal in the absence
of other reasonable alternatives.
The Bundesverband der Pharmazeutischen Industrie, BPI
(German Pharmaceutical Industry Association) [38] illus-
trated the value assessment of drugs under methodic
aspects with ten examples. These examples describe the
complexity of value assessment by demonstrating the
measurement of effectiveness, quality of life, compliance,
side effects and costs on different models. The introduc-
tion to the topic contains a general and technically well-
founded criticism of methods relating to value assessment
in medicine. This presentation of the components of
value assessment is a prerequisite for the following neces-
sary step of finding a consensus in which these compo-
nents are summarised into a value judgment for an
indication and a treatment method.
The drug manufacturer, Pfizer Germany, [39] recruited
scientists from different disciplines and institutions for a
pertinent discussion of the value of drugs. The didactically
valuable, comprehensible contributions reflect the differ-
ent understanding of the various methods which are
applied to describe value in the different disciplines. The
contributions appear to coincide in the opinion that a dif-
ferentiated judgment of the benefit for the individual
patients in everyday medical care is not possible. We are
not yet satisfied with this result because, when there is no
consensus on the value assessment, there is a risk that
arbitrarily chosen criteria will be legitimated either to
publicly finance health services which are of little patient
benefit or not to publicly finance beneficial services and,
thereby, restrict their availability to part of society. For
that reason we are strongly in favour of gaining a consen-
sus concerning the value assessment of health-care serv-
ices. Even if this consensus initially has severe limitations,
it makes more sense to begin the process of consensus
building now than later.
Perleth [40] and Busse [41] called attention to the grow-
ing importance of Health Technology Assessment (HTA)
Reports in the evaluation and reimbursement of health-
care services. Although the importance of these summary
reports is generally accepted, one must keep in mind that
there exist qualitative differences among these reports. If
the quality of scientific papers which are summarized in
HTA reports reveals errors and these are not mentioned in
the HTA report [42], a major pillar of our decision-making
processes could become instable. The compilation of
complex data with scientific methods does not necessarily
increase the reliability of their statements. In our own
interest we should consider whether quality-ensuring
measures should be introduced for these important com-
ponents.
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